Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Pemberton-Ross

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
European Heart Journal. Quality of Care & Clinical Outcomes|October 16, 2020
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in SwedenUlf Landmesser, Peter Lindgren, Emil Hagström, et al.
Lancet (London, England)|November 10, 2015
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical modelsMelissa A Penny, Robert Verity, Caitlin A Bever, et al.
The Lancet. Global Health|June 2, 2017
Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling studyOliver J Brady, Hannah C Slater, Peter Pemberton-Ross, et al.
The Lancet. Global Health|September 16, 2017
Model citizen - Authors' replyOliver J Brady, Hannah C Slater, Peter Pemberton-Ross, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 9, 2024
IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's DiseaseRon Handels, William L Herring, Farzam Kamgar, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
European Heart Journal. Quality of Care & Clinical Outcomes|October 16, 2020
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in SwedenUlf Landmesser, Peter Lindgren, Emil Hagström, et al.
Lancet (London, England)|November 10, 2015
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical modelsMelissa A Penny, Robert Verity, Caitlin A Bever, et al.
The Lancet. Global Health|June 2, 2017
Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling studyOliver J Brady, Hannah C Slater, Peter Pemberton-Ross, et al.
The Lancet. Global Health|September 16, 2017
Model citizen - Authors' replyOliver J Brady, Hannah C Slater, Peter Pemberton-Ross, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 9, 2024
IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's DiseaseRon Handels, William L Herring, Farzam Kamgar, et al.
Pageof 2